A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit

Cancer Immunology, Immunotherapy

Volumn 64, Issue 9, 2015, Pages 1123-1136

  Anastasopoulou, Eleftheria A ^a   Voutsas, Ioannis F ^a   Keramitsoglou, Theodora ^b   Gouttefangeas, Cécile ^c   Kalbacher, Hubert ^c   Thanos, Anastasios ^a   Papamichail, Michael ^a   Perez, Sonia A ^a   Baxevanis, Constantin N ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b HELENA VENIZELOU HOSPITAL   (Greece)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Biomarkers; Cancer vaccine; Clinical response; HLA; Immune response; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POLYPEPTIDE VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A24 ANTIGEN; HLA DRB1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; AE37 VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; HLA-DRB1*11 ANTIGEN; TUMOR MARKER;

ALLELE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG RESPONSE; GENE EXPRESSION; GENE FREQUENCY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; LONG TERM SURVIVAL; MALE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT RESPONSE; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS;

ALLELES; CANCER VACCINES; HLA-A24 ANTIGEN; HLA-DRB1 CHAINS; HUMANS; MALE; PILOT PROJECTS; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 84939564060     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1717-1     Document Type: Article

References (42)

1. Schlom J (2012) Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 104:599–613. doi:10.1093/jnci/djs033
2. Cheng ML, Fong L (2014) Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol 15:115–126. doi:10.1007/s11864-013-0267-z
3. May KF Jr, Gulley JL, Drake CG, Dranoff G, Kantoff PW (2011) Prostate cancer immunotherapy. Clin Cancer Res 17:5233–5238. doi:10.1158/1078-0432.CCR-10-3402
4. Baxevanis CN (2012) Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm. Expert Rev Vaccines 11:275–277. doi:10.1586/erv.11.193
5. Hoos A, Eggermont AM, Janetzki S et al (2010) Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:1388–1397. doi:10.1093/jnci/djq310
6. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14:135–146. doi:10.1038/nrc3670
7. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213–219
8. Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV (2012) Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother 61:1243–1253. doi:10.1007/s00262-012-1201-0
9. Helgadottir H, Andersson E, Villabona L et al (2009) The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma. Cancer Immunol Immunother 58:1599–1608. doi:10.1007/s00262-009-0669-8
10. Lu CC, Chen JC, Jin YT, Yang HB, Chan SH, Tsai ST (2003) Genetic susceptibility to nasopharyngeal carcinoma within the HLA-A locus in Taiwanese. Int J Cancer 103:745–751. doi:10.1002/ijc.10861
11. So T, Takenoyama M, Sugaya M, Yasuda M, Eifuku R, Yoshimatsu T, Osaki T, Yasumoto K (2001) Unfavorable prognosis of patients with non-small cell lung carcinoma associated with HLA-A2. Lung Cancer 32:39–46
12. Bain C, Merrouche Y, Puisieux I et al (1997) Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. Br J Cancer 75:283–286
13. Cortes J, Fayad L, Kantarjian H, O’Brien S, Lee MS, Talpaz M (1998) Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. Leukemia 12:455–462
14. Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK (2002) Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 20:2067–2075
15. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL (2004) HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6:517–527. doi:10.1016/j.ccr.2004.09.031
16. Ricciardelli C, Jackson MW, Choong CS, Stahl J, Marshall VR, Horsfall DJ, Tilley WD (2008) Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate 68:830–838. doi:10.1002/pros.20747
17. Shariat SF, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, Slawin KM, Karakiewicz PI (2007) Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. Clin Cancer Res 13:5377–5384. doi:10.1158/1078-0432.CCR-07-0330
18. Sotiriadou NN, Kallinteris NL, Gritzapis AD et al (2007) Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu + tumors. Cancer Immunol Immunother 56:601–613. doi:10.1007/s00262-006-0213-z
19. Voutsas IF, Gritzapis AD, Mahaira LG, Salagianni M, von Hofe E, Kallinteris NL, Baxevanis CN (2007) Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer 121:2031–2041. doi:10.1002/ijc.22936
20. Perez SA, Kallinteris NL, Bisias S et al (2010) Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res 16:3495–3506. doi:10.1158/1078-0432.CCR-10-0085
21. Perez SA, Anastasopoulou EA, Tzonis P, Gouttefangeas C, Kalbacher H, Papamichail M, Baxevanis CN (2013) AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial. Cancer Immunol Immunother 62:1599–1608. doi:10.1007/s00262-013-1461-3
22. Perez SA, Anastasopoulou EA, Papamichail M, Baxevanis CN (2014) AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction. Cancer Immunol Immunother 63:1141–1150. doi:10.1007/s00262-014-1582-3
23. Sperner-Unterweger B, Neurauter G, Klieber M, Kurz K, Meraner V, Zeimet A, Fuchs D (2011) Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers. Immunobiology 216:296–301. doi:10.1016/j.imbio.2010.07.010
24. Galon J, Mlecnik B, Bindea G et al (2014) Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 232:199–209. doi:10.1002/path.4287
25. Rammensee HG (1995) Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 7:85–96
26. Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis CN (2010) A new era in anticancer peptide vaccines. Cancer 116:2071–2080. doi:10.1002/cncr.24988
27. Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML (2003) Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 9:5559–5565
28. Sotiriadou R, Perez SA, Gritzapis AD et al (2001) Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 85:1527–1534. doi:10.1054/bjoc.2001.2089
29. Disis ML (2010) Immune regulation of cancer. J Clin Oncol 28:4531–4538. doi:10.1200/JCO.2009.27.2146
30. Hoon DS, Okamoto T, Wang HJ, Elashoff R, Nizze AJ, Foshag LJ, Gammon G, Morton DL (1998) Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? J Clin Oncol 16:1430–1437
31. Baxevanis CN, Papamichail M, Perez SA (2014) Therapeutic cancer vaccines: a long and winding road to success. Expert Rev Vaccines 13:131–144. doi:10.1586/14760584.2014.852961
32. Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M (2010) HER-2/neu as a target for cancer vaccines. Immunotherapy 2:213–226. doi:10.2217/imt.09.89
33. Cuppens K, Vansteenkiste J (2014) Vaccination therapy for non-small-cell lung cancer. Curr Opin Oncol 26:165–170. doi:10.1097/CCO.0000000000000052
34. Bioley G, Guillaume P, Luescher I et al (2009) HLA class I—associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine. Clin Cancer Res 15:299–306. doi:10.1158/1078-0432.CCR-08-1747
35. Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H (2010) Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med 207:2469–2477. doi:10.1084/jem.20092450
36. Toes RE, Ossendorp F, Offringa R, Melief CJ (1999) CD4 T cells and their role in antitumor immune responses. J Exp Med 189:753–756
37. Disis ML (2011) Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 60:433–442. doi:10.1007/s00262-010-0960-8
38. Baxevanis CN, Papamichail M, Perez SA (2015) Prostate cancer vaccines: the long road to clinical application. Cancer Immunol Immunother 64:401–408. doi:10.1007/s00262-015-1667-7
39. Arens R, van Hall T, van der Burg SH, Ossendorp F, Melief CJ (2013) Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Semin Immunol 25:182–190. doi:10.1016/j.smim.2013.04.008
40. Di Lorenzo G, Buonerba C, Kantoff PW (2011) Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 8:551–561. doi:10.1038/nrclinonc.2011.72
41. Gulley JL, Drake CG (2011) Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res 17:3884–3891. doi:10.1158/1078-0432.CCR-10-2656
42. Schweizer MT, Drake CG (2014) Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 33:641–655. doi:10.1007/s10555-013-9479-8